Literature DB >> 28255745

Health-related quality of life in patients receiving long-term opioid therapy: a systematic review with meta-analysis.

J Douglas Thornton1, Rashmi Goyat1, Nilanjana Dwibedi2, George A Kelley3.   

Abstract

PURPOSE: Over 25 million Americans reported having daily pain and between 5 and 8 million Americans used opioids to treat chronic pain in 2012. This is the first systematic review with meta-analysis to determine the effects of long-term opioid use on the Physical Component Summary (PCS) score and Mental Component Summary (MCS) scores of a Health-Related Quality of Life instrument in adults without opioid use disorder.
METHODS: The a priori eligibility criteria for the PubMed (MEDLINE), Scopus, and PsyINFO searches were (1) randomized controlled trial, (2) at least one opioid intervention group, (3) minimum of 4-week duration of opioid use, (4) comparative control group, and (5) adults ≥18 years that do not have dominant disease. The unit of analysis was the standardized mean difference effect size (Hedges's g). All results were pooled using random-effects models.
RESULTS: Of the 340 non-duplicate citations screened, 19 articles comprising 26 treatment comparisons and 6168 individuals (treatment n = 3160; comparators n = 3008 with duplicates removed) met the inclusion criteria for the systematic review. Thirteen treatment comparisons were available for the meta-analysis. Across all PCS analyses, small, statistically significant improvements were observed (opioid versus opioid only: g = 0.27, 95% CI 0.05-0.50, opioid versus placebo only: g = 0.18, 95% CI 0.08-0.28, and all studies combined: g = 0.22, 95% CI 0.11-0.32). There were small but not statistically significant changes on the MCS scores. Overall, high heterogeneity was present.
CONCLUSIONS: PCS scores improve with no change in MCS scores. However, long-term opioid trials are rare and only two trials included lasted longer than 1 year.

Entities:  

Keywords:  Health-related quality of life; Meta-analysis; Opioid; Randomized controlled trials; Systematic review

Mesh:

Substances:

Year:  2017        PMID: 28255745      PMCID: PMC5511070          DOI: 10.1007/s11136-017-1538-0

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  43 in total

Review 1.  Opioid therapy for chronic pain.

Authors:  Jane C Ballantyne; Jianren Mao
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

2.  Outcomes of follow-up visits to chronic nonmalignant pain patients.

Authors:  Liv M H Frich; Jan Sorensen; Susanne Jacobsen; Bente Fohlmann; Jette Højsted
Journal:  Pain Manag Nurs       Date:  2010-11-20       Impact factor: 1.929

3.  Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen.

Authors:  Robert M Bennett; Jeff Schein; Mark R Kosinski; David J Hewitt; Donna M Jordan; Norman R Rosenthal
Journal:  Arthritis Rheum       Date:  2005-08-15

4.  A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.

Authors:  Heinrich Binsfeld; Leszek Szczepanski; Sandra Waechter; Ute Richarz; Rainer Sabatowski
Journal:  Pain Pract       Date:  2010 Sep-Oct       Impact factor: 3.183

5.  Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy.

Authors:  C Peter N Watson; Dwight Moulin; Judith Watt-Watson; Allan Gordon; John Eisenhoffer
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

6.  Randomized versus historical controls for clinical trials.

Authors:  H Sacks; T C Chalmers; H Smith
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

7.  A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial.

Authors:  Richard L Rauck; Stephen A Bookbinder; Timothy R Bunker; Christopher D Alftine; Steven Gershon; Egbert de Jong; Andres Negro-Vilar; Richard Ghalie
Journal:  J Opioid Manag       Date:  2007 Jan-Feb

8.  A randomized, double-blind, double-dummy comparison of short- and long-acting dihydrocodeine in chronic non-malignant pain.

Authors:  Line Pedersen; Petter Christian Borchgrevink; Harald Petter Breivik; Olav Magnus Søndenå Fredheim
Journal:  Pain       Date:  2013-12-15       Impact factor: 6.961

9.  Credibility matters: mind the gap.

Authors:  Andrea C Skelly
Journal:  Evid Based Spine Care J       Date:  2014-04

10.  Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine.

Authors:  Eija Kalso; Karen H Simpson; Robert Slappendel; Joachim Dejonckheere; Ute Richarz
Journal:  BMC Med       Date:  2007-12-21       Impact factor: 8.775

View more
  3 in total

1.  Association of current and past opioid use disorders with health-related quality of life and employment among US adults.

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  Drug Alcohol Depend       Date:  2019-04-23       Impact factor: 4.492

2.  Opioid and Other Medication Use and General Health Status in a Cohort of Older Adults.

Authors:  Paul F Pinsky; Danielle Durham; Scott Strassels
Journal:  Gerontology       Date:  2021-03-10       Impact factor: 5.140

3.  Multicentre cross-sectional clinical evaluation study about quality of life in adults with disorders/differences of sex development (DSD) compared to country specific reference populations (dsd-LIFE).

Authors:  Marion Rapp; Esther Mueller-Godeffroy; Peter Lee; Robert Roehle; Baudewijntje P C Kreukels; Birgit Köhler; Anna Nordenström; Claire Bouvattier; Ute Thyen
Journal:  Health Qual Life Outcomes       Date:  2018-04-03       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.